JPH0666808A - Chromogen measurement method - Google Patents
Chromogen measurement methodInfo
- Publication number
- JPH0666808A JPH0666808A JP24119892A JP24119892A JPH0666808A JP H0666808 A JPH0666808 A JP H0666808A JP 24119892 A JP24119892 A JP 24119892A JP 24119892 A JP24119892 A JP 24119892A JP H0666808 A JPH0666808 A JP H0666808A
- Authority
- JP
- Japan
- Prior art keywords
- absorbance
- chyle
- wavelength
- hemoglobin
- bilirubin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/314—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry with comparison of measurements at specific and non-specific wavelengths
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/314—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry with comparison of measurements at specific and non-specific wavelengths
- G01N2021/3148—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry with comparison of measurements at specific and non-specific wavelengths using three or more wavelengths
Landscapes
- Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は乳び（濁り）、ヘモグロ
ビン（溶血）、ビリルビン（黄疸）などのクロモゲンを
含む検体の多項目生化学分析において、乳び、ヘモグロ
ビン、ビリルビンを定量する方法に関するものである。TECHNICAL FIELD The present invention relates to a method for quantifying chyle, hemoglobin and bilirubin in a multi-item biochemical analysis of a sample containing chromogens such as chyle (turbidity), hemoglobin (hemolysis) and bilirubin (jaundice). It is a thing.
【０００２】[0002]
【従来の技術】臨床検査で分析測定しようとする検体に
含まれる乳び、ヘモグロビン及びビリルビンの３種のク
ロモゲンを同じ検体から同時期に定量する方法として、
可視光波長域のうちの乳びの影響はあるがヘモグロビン
及びビリルビンの影響が実質的にない長波長域での適正
な波長における吸光度を測定して乳びの程度を求め、可
視光波長域のうちのビリルビンの影響が実質的にない中
波長域での適正な波長における吸光度の値及び長波長域
における測定値に基づいてヘモグロビンの程度を求め、
可視光波長域のうちのヘモグロビンの影響がある短波長
域での適正な波長における吸光度の値及び中波長域にお
ける測定値に基づいてビリルビンの程度を求めることが
提案されている（特公昭６１−１９９３３号公報参
照）。2. Description of the Related Art As a method for quantifying three types of chromogens of chyle, hemoglobin and bilirubin contained in a sample to be analyzed and measured in a clinical test from the same sample at the same time,
There is an influence of chyle in the visible light wavelength range, but the influence of hemoglobin and bilirubin is not substantially measured, and the degree of chyle is obtained by measuring the absorbance at an appropriate wavelength in a long wavelength range, The degree of hemoglobin is determined based on the absorbance value at a proper wavelength in the medium wavelength range where the effect of bilirubin is not present and the measured value in the long wavelength range,
It has been proposed to determine the degree of bilirubin based on the value of absorbance at an appropriate wavelength in the short wavelength region where the influence of hemoglobin is present in the visible light region and the measured value in the intermediate wavelength region (Japanese Patent Publication No. 61- (See Japanese Patent Publication No. 19933).
【０００３】[0003]
【発明が解決しようとする課題】上記の引用例において
は、乳び度を求めるために、ヘモグロビン及びビリルビ
ンの影響が実質的にない長波長域での２波長で吸光度を
求め、その吸光度差に基準液で求めた単位濁度当たりの
吸光度差を表わす一定の定数をかけて中波長域での乳び
度とし、その乳び度を中波長域での２波長の吸光度差か
ら引くことによりヘモグロビン度を算出している。しか
し、乳びに関しては波長間の吸光度変換を表わす定数は
検体中の粒子の大きさに関係する値であり、検体によっ
て異なる。そのため、もしその定数を用いるとすれば検
体ごとに求めなければならないにも拘らず、検体が変わ
っても一定であるとしているので、その定数を用いて算
出されるヘモグロビンとビリルビンの値には誤差を含ん
でいる。また、その引用例の方法では、３種の各クロモ
ゲンについて２波長ずつ測定しなければならないので、
合計で６波長での測定が必要になる。In the above cited example, in order to obtain the milkiness, the absorbance is calculated at two wavelengths in the long wavelength range where the effects of hemoglobin and bilirubin are not substantially obtained, and the difference in absorbance is calculated. Hemoglobin is obtained by multiplying the chyle degree in the mid-wavelength range by multiplying a constant constant that represents the difference in absorbance per unit turbidity obtained with the reference solution, and subtracting the chyle degree from the difference in the two-wavelength absorbance in the mid-wavelength range. The degree is calculated. However, with respect to chyle, the constant representing the absorbance conversion between wavelengths is a value related to the size of particles in the sample and varies depending on the sample. Therefore, if the constant is used, it is said that it is constant even if the sample changes, even though it has to be calculated for each sample.Therefore, there is an error in the values of hemoglobin and bilirubin calculated using the constant. Is included. Also, in the method of the cited example, since it is necessary to measure two wavelengths for each of the three types of chromogens,
A total of 6 wavelengths must be measured.
【０００４】そこで、本発明の第１の目的は、乳びの吸
光度が粒子の大きさの関数であることを考慮して乳び、
ヘモグロビン及びビリルビンを正しく算出することであ
る。本発明の第２の目的は、測定波長数が多いほど誤差
は小さくなるが、クロモゲンの算出に必要な測定波長数
を少なくすることによって測定時間を短縮し、測定装置
を簡略化することである。Therefore, the first object of the present invention is to consider that the absorbance of the chyle is a function of the particle size,
Correct calculation of hemoglobin and bilirubin. A second object of the present invention is to reduce the error as the number of measurement wavelengths increases, but to shorten the measurement time by simplifying the measurement device by reducing the number of measurement wavelengths required for chromogen calculation. .
【０００５】[0005]
【課題を解決するための手段】本発明では、懸濁物質が
混在する検体にブランク反応用試薬を混合して検体ブラ
ンク液を調製し、この検体ブランク液の吸光度を乳びの
吸収がありヘモグロビンとビリルビンの吸収が実質的に
ない波長を含む少なくとも４種の波長により吸光度を測
定し、乳びに関しては吸光度が波長の指数関数で表され
ると仮定して波長−吸光度の回帰関数を求め、ヘモグロ
ビンとビリルビンに関しては異なる波長での吸光度間に
予め求められた一定の関係があると仮定して、前記測定
波長における吸光度に関する連立一次方程式を作り、そ
れを解いて乳び、ヘモグロビンおよびビリルビンの程度
を算出する。ブランク反応用試薬は各種の分析項目の測
定に使用される既知の種々の反応試薬から反応成分を除
いたもので上記の測定波長域に吸収をもたないもの、例
えば反応試薬の溶媒に使用される緩衝液、生理食塩水、
水などである。According to the present invention, a sample blank solution is prepared by mixing a blank reaction reagent with a sample in which suspended substances are mixed, and the absorbance of this sample blank solution is determined by absorption of chyle. Absorbance of bilirubin and the absorbance is measured by at least four types of wavelengths including wavelengths that do not substantially exist, and for chyle, the absorbance is calculated by assuming that the absorbance is represented by an exponential function of wavelength, and a regression function of the absorbance is obtained, For hemoglobin and bilirubin, assuming that there is a predetermined relationship between the absorbances at different wavelengths, make a simultaneous linear equation for the absorbances at the measurement wavelengths and solve it to determine the extent of chyle, hemoglobin and bilirubin. To calculate. A blank reaction reagent is one obtained by removing reaction components from various known reaction reagents used for measurement of various analytical items and having no absorption in the above measurement wavelength range, for example, used as a solvent for reaction reagents. Buffer solution, physiological saline,
For example, water.
【０００６】[0006]
【作用】一定量の検体に一定量のブランク反応用試薬を
混合して検体ブランク液を調製し、この検体ブランク液
について測定波長λ1，λ2，λ3，λ4で測定したときの
吸光度をそれぞれＡ(λ1），Ａ(λ2），Ａ(λ3），Ａ
(λ4）とすると、次の式が成り立つ。 Ａ(λ1）＝Ａｈ(λ1）＋Ａｂ(λ1）＋Ａｔ(λ1） Ａ(λ2）＝Ａｈ(λ2）＋Ａｂ(λ2）＋Ａｔ(λ2） Ａ(λ3）＝Ａｈ(λ3）＋Ａｂ(λ3）＋Ａｔ(λ3） Ａ(λ4）＝ Ａｔ(λ4） ここで、Ａｈ(λ），Ａｂ(λ），Ａｔ(λ）はそれぞれ
波長λにおけるヘモグロビン、ビリルビン、乳びによる
吸光度であり、波長λ4は検体が乳びに起因する吸光度
しかもたない測定波長であるとする。各クロモゲンの吸
収スペクトルを図１に示す。Ｈはヘモグロビン、Ｂはビ
リルビン、ｔは乳びを表している。測定波長λ1，λ2，
λ3，λ4は例えば３４０，４１０，４５０，６６０ｎｍ
とする。[Function] Absorbance of a sample blank solution prepared by mixing a certain amount of sample with a certain amount of blank reaction reagent, and measuring this sample blank solution at measurement wavelengths λ 1 , λ 2 , λ 3 , and λ 4. Are A (λ 1 ), A (λ 2 ), A (λ 3 ), A
(λ 4 ), the following equation holds. A (λ 1 ) = Ah (λ 1 ) + Ab (λ 1 ) + At (λ 1 ) A (λ 2 ) = Ah (λ 2 ) + Ab (λ 2 ) + At (λ 2 ) A (λ 3 ) = Ah ( λ 3 ) + Ab (λ 3 ) + At (λ 3 ) A (λ 4 ) = At (λ 4 ), where Ah (λ), Ab (λ), At (λ) are hemoglobin, bilirubin at wavelength λ, and It is the absorbance due to chyle, and the wavelength λ 4 is the measurement wavelength at which the sample has only the absorbance due to chyle. The absorption spectrum of each chromogen is shown in FIG. H represents hemoglobin, B represents bilirubin, and t represents chyle. Measurement wavelength λ 1 , λ 2 ,
λ 3 and λ 4 are, for example, 340, 410, 450, 660 nm
And
【０００７】乳びに起因する吸光度は Ａｔ(λ）＝ａλb と表わすことができる（特開昭６２−１７９６３９号参
照）。ここで、ａは粒子の数に起因する定数、ｂは平均
粒子径に起因する定数で、ａ，ｂはともに検体によって
異なる。一方、ヘモグロビンとビリルビンに関しては検
体が異なっても吸収スペクトルの形状は変わらないこと
が実験的確かめられているので、ある波長の吸光度から
別の波長の吸光度へは予め求められた係数をかけること
によって波長間の吸光度換算ができる。The absorbance due to chyle can be expressed as At (λ) = aλ b (see JP-A-62-179639). Here, a is a constant resulting from the number of particles, b is a constant resulting from the average particle diameter, and both a and b differ depending on the sample. On the other hand, regarding hemoglobin and bilirubin, it has been experimentally confirmed that the shape of the absorption spectrum does not change even if the sample is different, so by multiplying the absorbance of one wavelength to the absorbance of another wavelength by a previously determined coefficient. It is possible to convert absorbance between wavelengths.
【０００８】これらの関係を用い、３４０ｎｍでの吸光
度に合わせて上記の式を変形すると次のようになる。 Ａ(340）＝Ａｈ(340） ＋ Ａｂ(340）＋Ａｔ(340） Ａ(410）＝Ｋ1・Ａｈ(340）＋Ｋ2・Ａｂ(340）＋Ａｔ(410） Ａ(450）＝Ｋ3・Ａｈ(340）＋Ｋ4・Ａｂ(340）＋Ａｔ(450） Ａ(660）＝ Ａｔ(660） ここで、Ｋ1はヘモグロビンの吸光度を測定波長３４０
ｎｍでの吸光度から測定波長４１０ｎｍでの吸光度に換
算する換算係数、Ｋ3はヘモグロビンの吸光度を測定波
長３４０ｎｍでの吸光度から測定波長４５０ｎｍでの吸
光度に換算する換算係数、Ｋ2はビリルビンの吸光度を
測定波長３４０ｎｍでの吸光度から測定波長４１０ｎｍ
での吸光度に換算する換算係数、Ｋ4はビリルビンの吸
光度を測定波長３４０ｎｍでの吸光度から測定波長４５
０ｎｍでの吸光度に換算する換算係数である。Using the above relationships, the above equation can be modified according to the absorbance at 340 nm as follows. A (340) = Ah (340) + Ab (340) + At (340) A (410) = K 1 · Ah (340) + K 2 · Ab (340) + At (410) A (450) = K 3 · Ah (340) + K 4 · Ab (340) + At (450) A (660) = At (660) where K 1 is the measurement wavelength of the absorbance of hemoglobin 340
The conversion coefficient for converting the absorbance at nm to the absorbance at the measurement wavelength of 410 nm, K 3 is the conversion coefficient for converting the absorbance of hemoglobin to the absorbance at the measurement wavelength of 450 nm from the absorbance at the measurement wavelength of 340 nm, and K 2 is the absorbance of bilirubin. From absorbance at measurement wavelength 340 nm to measurement wavelength 410 nm
A conversion coefficient for converting the absorbance at 4 to K 4 is the absorbance of bilirubin from the absorbance at the measurement wavelength of 340 nm to the measurement wavelength of 45.
It is a conversion coefficient for converting the absorbance at 0 nm.
【０００９】Ａｔ(λ）＝ａ・λbの関係を用いて上記の
式をまとめると次のようになる。 {(K2・K3-K1・K4)A(340)−(K3-K4)A(410)＋(K1-K2)A(450)}／A(660) ＝{(K2・K3-K1・K4)・340b−(K3-K4)・410b＋(K1-K2)・450b}／660b The above equations can be summarized as follows using the relationship of At (λ) = aλ b . {(K 2・ K 3 -K 1・ K 4 ) A (340)-(K 3 -K 4 ) A (410) + (K 1 -K 2 ) A (450)} / A (660) = { (K 2・ K 3 -K 1・ K 4 ) ・ 340 b − (K 3 -K 4 ) ・ 410 b + (K 1 -K 2 ) ・ 450 b } / 660 b
【００１０】この式で、左辺は一定値であり、ｂを近似
計算により求めることができ、ａは ａ＝A(660)／660b で求めることができる。また、 Ａｈ(410）＝Ａ(410）−Ｋ5・Ａｂ(450）−ａ410b Ａｂ(450）＝Ａ(450）−Ｋ6・Ａｈ(410）−ａ450b となる。ここで、Ｋ5はビリルビンの吸光度を測定波長
４１０ｎｍでの吸光度から測定波長４５０ｎｍでの吸光
度に換算する換算係数、Ｋ6はヘモグロビンの吸光度を
測定波長４５０ｎｍでの吸光度から測定波長４１０ｎｍ
での吸光度に換算する換算係数である。In this equation, the left side is a constant value, b can be obtained by approximate calculation, and a can be obtained by a = A (660) / 660 b . Further, Ah (410) = A ( 410) -K 5 · Ab (450) -a410 b Ab (450) = A (450) -K 6 · Ah (410) becomes -a450 b. Here, K 5 is a conversion coefficient for converting the absorbance of bilirubin from the absorbance at the measurement wavelength of 410 nm to the absorbance at the measurement wavelength of 450 nm, and K 6 is the absorbance of hemoglobin from the absorbance at the measurement wavelength of 450 nm to the measurement wavelength of 410 nm.
It is a conversion coefficient for converting the absorbance at.
【００１１】これにより、 Ａｈ(410）＝{A(410)-Ｋ5・A(450)-a・410b+Ｋ5・a・450b}／(1-Ｋ5・K6) Ａｂ(450）＝{Ｋ6・A(410)-A(450)-K6・a・410b+a・450b}／(Ｋ5・K6-1) となり、ヘモグロビンとビリルビンの最大吸収波長に近
い波長におけるそれぞれの成分単独の吸光度が求められ
る。求められた吸光度に濃度換算係数及び希釈倍率を乗
ずることによりヘモグロビンとビリルビンを定量するこ
とができる。As a result, Ah (410) = {A (410) -K 5 .A (450) -a.410 b + K 5 .a.450 b } / (1-K 5 .K 6 ) Ab ( 450) = {K 6 · A (410) -A (450) -K 6 · a · 410 b + a · 450 b } / (K 5 · K 6 -1), which is the maximum absorption wavelength of hemoglobin and bilirubin. The absorbance of each component alone at near wavelengths is determined. Hemoglobin and bilirubin can be quantified by multiplying the obtained absorbance by the concentration conversion coefficient and the dilution rate.
【００１２】[0012]
【実施例】ヘモグロビンと乳びを含む実検体を生理食塩
水で３１倍に希釈したものを測定した例を図２に示す。
１０ｎｍごとに吸収を測定し、その測定点（黒丸）を結
んだものが図中の Sample として示した吸収スペクトル
である。その測定点のうち、測定波長３４０，４１０，
４５０，６６０ｎｍでの吸光度を用いて上記の演算を適
用して、乳びによる濁りのスペクトルとして示したのが
ｔであり、実測吸光度から濁りの予想吸光度を差し引い
て示したスペクトルがＨである。算出されたａ＝６.２
６８×１０8、ｂ＝−２.６９３、ヘモグロビンの濃度は
５２ｍｇ／ｄｌとなった。[Examples] FIG. 2 shows an example of measurement of a real sample containing hemoglobin and chyle diluted 31 times with physiological saline.
Absorption was measured every 10 nm and the measurement points (black circles) were connected to each other to form the absorption spectrum shown as Sample in the figure. Of the measurement points, the measurement wavelengths 340, 410,
By applying the above calculation using the absorbances at 450 and 660 nm, t is shown as a spectrum of turbidity due to chyle, and H is the spectrum obtained by subtracting the expected absorbance of turbidity from the measured absorbance. Calculated a = 6.2
68 × 10 8 , b = −2.693, and hemoglobin concentration was 52 mg / dl.
【００１３】ヘモグロビン、ビリルビン及び乳びを含む
実検体を生理食塩水で３１倍に希釈したものを測定した
例を図３に示す。測定は図２と同じであり、１０ｎｍご
とに吸収を測定し、その測定点（黒丸）を結んだものが
図中の Sample として示した吸収スペクトルである。こ
の場合もその測定点のうち、測定波長３４０，４１０，
４５０，６６０ｎｍでの吸光度を用いて上記の演算を適
用して、乳びによる濁りのスペクトルとして示したのが
ｔであり、実測吸光度から濁りの予想吸光度を差し引い
て示したスペクトルがＨ＋Ｂである。算出されたａ＝
４.１８４×１０7、ｂ＝−２.０８９、ヘモグロビンの
濃度は１１ｍｇ／ｄｌ、ビリルビンの濃度は１９ｍｇ／
ｄｌとなった。別に反応試薬を加えて吸光度を測定する
分析において、ヘモグロビンとビリルビンに関しては各
波長間における吸光度換算係数を求めておけば、乳びに
関してはＡ＝ａλbの関係からその測定波長におけるこ
れらクロモゲンに関しての吸光度が予想できるので、試
料量／試薬量比を考慮に入れて実測吸光度から差し引く
ことにより、反応のみによる真の吸光度が分かるので、
定量値の補正や限界吸光度の補正などを行なうことがで
きる。FIG. 3 shows an example in which an actual sample containing hemoglobin, bilirubin and chyle was diluted 31 times with physiological saline and measured. The measurement is the same as in FIG. 2, and absorption is measured every 10 nm and the measurement points (black circles) are connected to each other to form an absorption spectrum shown as Sample in the figure. Also in this case, among the measurement points, the measurement wavelengths 340, 410,
By applying the above calculation using the absorbances at 450 and 660 nm, t is shown as the spectrum of turbidity due to chyle, and the spectrum obtained by subtracting the expected absorbance of turbidity from the measured absorbance is H + B. Calculated a =
4.184 × 10 7 , b = −2.089, hemoglobin concentration 11 mg / dl, bilirubin concentration 19 mg /
It became dl. Separately, in an analysis in which a reaction reagent is added to measure the absorbance, if the absorbance conversion coefficient between each wavelength is obtained for hemoglobin and bilirubin, for chyle, the relation between these chromogens at the measurement wavelength is determined from the relation of A = aλ b . Since the absorbance can be predicted, the true absorbance due to the reaction alone can be found by subtracting it from the measured absorbance taking into account the sample amount / reagent amount ratio.
It is possible to correct the quantitative value and the limit absorbance.
【００１４】[0014]
【発明の効果】本発明では乳びに関しては吸光度が波長
の指数関数で表されると仮定して波長−吸光度の回帰関
数を求めるので、乳び度の測定を検体中の粒子径に左右
されることなく実行することができる。そして、乳び度
が正しく求まるので、それから導かれるヘモグロビンや
ビリルビンの算出値も正確になる。各クロモゲンを正確
に求めることができるので、分析項目に対しての吸光度
補正を正確に行なうことができる。In the present invention, regarding the chyle, the wavelength-absorbance regression function is obtained on the assumption that the absorbance is represented by the exponential function of the wavelength. Therefore, the measurement of the chyle depends on the particle size in the sample. Can be done without. Then, the degree of chyle is accurately obtained, and the calculated values of hemoglobin and bilirubin derived therefrom are also accurate. Since each chromogen can be accurately obtained, the absorbance correction for the analysis item can be accurately performed.
【図１】各クロモゲンの吸光度を示す図である。FIG. 1 is a diagram showing the absorbance of each chromogen.
【図２】ヘモグロビンと乳びを含む検体を測定した実施
例における検体とクロモゲンの吸収スペクトルを示す図
である。FIG. 2 is a diagram showing absorption spectra of a sample and chromogen in an example in which a sample containing hemoglobin and chyle was measured.
【図３】ヘモグロビン、ビリルビン及び乳びを含む検体
を測定した実施例における検体とクロモゲンの吸収スペ
クトルを示す図である。FIG. 3 is a diagram showing absorption spectra of a sample and chromogen in an example in which a sample containing hemoglobin, bilirubin, and chyle was measured.
Claims (1)
用試薬を混合して検体ブランク液を調製し、この検体ブ
ランク液の吸光度を乳びの吸収がありヘモグロビンとビ
リルビンの吸収が実質的にない波長を含む少なくとも４
種の波長により吸光度を測定し、乳びに関しては吸光度
が波長の指数関数で表されると仮定して波長−吸光度の
回帰関数を求め、ヘモグロビンとビリルビンに関しては
異なる波長での吸光度間に予め求められた一定の関係が
あると仮定して、前記測定波長における吸光度に関する
連立一次方程式を作り、それを解いて乳び、ヘモグロビ
ンおよびビリルビンの程度を算出するクロモゲンの測定
方法。1. A sample blank solution is prepared by mixing a blank reaction reagent with a sample in which suspended substances are mixed, and the absorbance of this sample blank solution has absorption of chyle and absorption of hemoglobin and bilirubin is substantially At least 4 including no wavelength
Absorbance is measured by the wavelength of the seed, and for chyle, the wavelength-absorbance regression function is obtained assuming that the absorbance is represented by an exponential function of wavelength, and for hemoglobin and bilirubin, it is determined in advance between the absorbances at different wavelengths. A method for measuring chromogen in which simultaneous linear equations regarding the absorbance at the measurement wavelength are created, and are solved to calculate the degrees of chyle, hemoglobin and bilirubin on the assumption that there is a certain relationship.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24119892A JP3203798B2 (en) | 1992-08-17 | 1992-08-17 | How to measure chromogen |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24119892A JP3203798B2 (en) | 1992-08-17 | 1992-08-17 | How to measure chromogen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0666808A true JPH0666808A (en) | 1994-03-11 |
| JP3203798B2 JP3203798B2 (en) | 2001-08-27 |
Family
ID=17070670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP24119892A Expired - Fee Related JP3203798B2 (en) | 1992-08-17 | 1992-08-17 | How to measure chromogen |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3203798B2 (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100343753B1 (en) * | 2000-02-17 | 2002-07-20 | 강건 | Instrument for determining Bilirubin concentration and Hemoglobin content |
| JP2003004753A (en) * | 2001-06-18 | 2003-01-08 | Aloka Co Ltd | Dispensing conformity-determining apparatus |
| JP2007263907A (en) * | 2006-03-30 | 2007-10-11 | Sysmex Corp | Blood coagulation time measuring device |
| JP2007315942A (en) * | 2006-05-26 | 2007-12-06 | Sekisui Chem Co Ltd | Method of measuring hemoglobin types |
| WO2009057659A1 (en) * | 2007-10-30 | 2009-05-07 | Arkray, Inc. | Method for analyzing sample and its device |
| US7760340B2 (en) | 2006-03-16 | 2010-07-20 | Sysmex Corporation | Sample analyzer |
| US7842509B2 (en) | 2006-03-30 | 2010-11-30 | Sysmex Corporation | Blood analyzer and blood analyzing method |
| JP2014521095A (en) * | 2011-07-18 | 2014-08-25 | シーメンス ヘルスケア ダイアグノスティクス プロダクツ ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | Method and system for measuring the concentration of a substance in a body fluid |
| JP2016138886A (en) * | 2015-01-27 | 2016-08-04 | シーメンス ヘルスケア ダイアグノスティクス プロダクツ ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | Method of determining lipids and other interfering substances in body fluid samples |
| WO2019171703A1 (en) * | 2018-03-05 | 2019-09-12 | オリンパス株式会社 | Endoscope system |
| JP2020008578A (en) * | 2018-07-03 | 2020-01-16 | シーメンス ヘルスケア ダイアグノスティクス プロダクツ ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | Method for determining lipids, hemoglobin and bilirubin in body fluid samples |
| WO2020229957A1 (en) * | 2019-05-10 | 2020-11-19 | Inpeco Holding Ltd. | Device and process for screening of a biological sample |
| CN112710620A (en) * | 2021-01-05 | 2021-04-27 | 广州睿贝医学科技有限公司 | Method, device, equipment, medium and application for detecting accurate DNA concentration |
| CN112834440A (en) * | 2021-01-05 | 2021-05-25 | 广州睿贝医学科技有限公司 | Method, device, equipment, medium and application for detecting concentration of precise RNA |
-
1992
- 1992-08-17 JP JP24119892A patent/JP3203798B2/en not_active Expired - Fee Related
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100343753B1 (en) * | 2000-02-17 | 2002-07-20 | 강건 | Instrument for determining Bilirubin concentration and Hemoglobin content |
| JP2003004753A (en) * | 2001-06-18 | 2003-01-08 | Aloka Co Ltd | Dispensing conformity-determining apparatus |
| US7760340B2 (en) | 2006-03-16 | 2010-07-20 | Sysmex Corporation | Sample analyzer |
| EP1845363A3 (en) * | 2006-03-16 | 2012-03-28 | Sysmex Corporation | Sample analyzer |
| EP2645086A2 (en) | 2006-03-16 | 2013-10-02 | Sysmex Corporation | Sample analyzer |
| JP2007263907A (en) * | 2006-03-30 | 2007-10-11 | Sysmex Corp | Blood coagulation time measuring device |
| US7842509B2 (en) | 2006-03-30 | 2010-11-30 | Sysmex Corporation | Blood analyzer and blood analyzing method |
| JP2007315942A (en) * | 2006-05-26 | 2007-12-06 | Sekisui Chem Co Ltd | Method of measuring hemoglobin types |
| US9176049B2 (en) | 2007-10-30 | 2015-11-03 | Arkray Inc | Method of optical analysis using reference cell and base plate correction and apparatus thereof |
| WO2009057659A1 (en) * | 2007-10-30 | 2009-05-07 | Arkray, Inc. | Method for analyzing sample and its device |
| JP5442447B2 (en) * | 2007-10-30 | 2014-03-12 | アークレイ株式会社 | Sample analysis method and apparatus |
| JP2014521095A (en) * | 2011-07-18 | 2014-08-25 | シーメンス ヘルスケア ダイアグノスティクス プロダクツ ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | Method and system for measuring the concentration of a substance in a body fluid |
| JP2016138886A (en) * | 2015-01-27 | 2016-08-04 | シーメンス ヘルスケア ダイアグノスティクス プロダクツ ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | Method of determining lipids and other interfering substances in body fluid samples |
| WO2019171703A1 (en) * | 2018-03-05 | 2019-09-12 | オリンパス株式会社 | Endoscope system |
| US11723513B2 (en) | 2018-03-05 | 2023-08-15 | Olympus Corporation | Endoscope system and image processing method |
| JP2020008578A (en) * | 2018-07-03 | 2020-01-16 | シーメンス ヘルスケア ダイアグノスティクス プロダクツ ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | Method for determining lipids, hemoglobin and bilirubin in body fluid samples |
| WO2020229957A1 (en) * | 2019-05-10 | 2020-11-19 | Inpeco Holding Ltd. | Device and process for screening of a biological sample |
| CN113950620A (en) * | 2019-05-10 | 2022-01-18 | 英派克股份有限公司 | Apparatus and process for screening biological samples |
| US11965824B2 (en) | 2019-05-10 | 2024-04-23 | Inpeco SA | Device and process for screening of a biological sample |
| CN113950620B (en) * | 2019-05-10 | 2024-05-28 | 英派克股份有限公司 | Apparatus and process for screening biological samples |
| CN112710620A (en) * | 2021-01-05 | 2021-04-27 | 广州睿贝医学科技有限公司 | Method, device, equipment, medium and application for detecting accurate DNA concentration |
| CN112834440A (en) * | 2021-01-05 | 2021-05-25 | 广州睿贝医学科技有限公司 | Method, device, equipment, medium and application for detecting concentration of precise RNA |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3203798B2 (en) | 2001-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2016390B1 (en) | A method and a system for quantitative hemoglobin determination | |
| EP1698883B1 (en) | Method of determining total hemoglobin concentration in undiluted and unhemolyzed whole blood | |
| US4013417A (en) | Analyzer for the determination of hemoglobin and other related compounds in whole blood and hemoglobin solutions | |
| JP5006441B2 (en) | Whole blood analysis | |
| US4157871A (en) | System for rate immunonephelometric analysis | |
| JP3203798B2 (en) | How to measure chromogen | |
| EP1023583B1 (en) | Method for measurement of blood substitutes | |
| US20070190637A1 (en) | Apparatus for handling fluids | |
| CN102854177B (en) | Method for determining methemoglobin content MetHb% in sample to be tested through Raman spectroscopy | |
| Parks et al. | Carboxyhemoglobin determination by second-derivative spectroscopy. | |
| JPS6332132B2 (en) | ||
| BRPI0822570B1 (en) | IN VITRO PROCESS FOR DETERMINING HEMOGLOBIN CONCENTRATION IN A SAMPLE OF DILUTED BLOOD | |
| JP3780599B2 (en) | Method for measuring antigen-antibody reaction substance | |
| JPS6118982B2 (en) | ||
| JPH0514855B2 (en) | ||
| JPH0593725A (en) | Prozone adjustment and analysis method in antigen-antibody reaction | |
| Liedtke et al. | Centrifugal analysis with automated sequential reagent addition: measurement of serum calcium. | |
| EP0433629B1 (en) | A method for the qualitative and quantitative determination of antibodies against bacterial antigens by means of the photometric measurement of agglutination | |
| JPH0359461A (en) | Automatic biochemical analysis apparatus | |
| JPS62179639A (en) | Multi-item biochemical analysis | |
| JPS61272637A (en) | Measuring instrument for polarized fluorescent light | |
| JPH07218507A (en) | Immuno nephelometry | |
| JP3204697B2 (en) | Automatic analysis method | |
| JPS6229016B2 (en) | ||
| JPS63103945A (en) | Method for measuring information in serum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 7 Free format text: PAYMENT UNTIL: 20080629 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 8 Free format text: PAYMENT UNTIL: 20090629 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100629 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 9 Free format text: PAYMENT UNTIL: 20100629 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110629 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 10 Free format text: PAYMENT UNTIL: 20110629 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 11 Free format text: PAYMENT UNTIL: 20120629 |
|
| LAPS | Cancellation because of no payment of annual fees |